skip to content
Primary navigation


Drug - Korlym (mifepristone) [Corcept Therapeutics]

September 2012

Therapeutic area - Cushing's Syndrome

Approval criteria

Patient has a diagnosis of endogenous Cushing's Syndrome.

Background information

Korlym (mifepristone) is used to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing’s syndrome. The drug was approved for use in patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Korlym should never be used by pregnant women.

In Cushing's Syndrome mifepristone should be considered the treatment of last resort to be employed only when other potential treatments, both pharmacological and surgical, have failed or are not practical.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top